Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmaC251 challenge

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 4028-4036

  Florese, Ruth H ^a   Van Rompay, Koen K A ^b   Aldrich, Kris ^a   Forthal, Donald N ^c   Landucci, Gary ^c   Mahalanabis, Madhumita ^d   Haigwood, Nancy ^d,e   Venzon, David ^a   Kalyanaraman, Vaniambadi S ^f   Marthas, Marta L ^b   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; EUTHANASIA; LYMPHOCYTE COUNT; MACACA; MONKEY DISEASE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

EID: 33748482187     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.4028     Document Type: Article

References (43)

1. Sawyer, L. A., D. A. Katzenstein, R. M. Hendry, E. J. Boone, L. K. Vujcic, C. C. Williams, S. L. Zeger, A. J. Saah, C. R. Rinaldo, Jr., J. P. Phair, et al. 1990. Possible beneficial effects of neutralizing antibodies and antibody-dependent cell mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6: 341-356.
2. Tyler, D. S., H. K. Lyerly, and K. J. Weinhold. 1989. Anti-HIV 1 ADCC. AIDS Res. Hum. Retroviruses 5: 557-563.
3. Ahmad, A., and J. Menezes. 1996. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 10: 258-266.
4. + lymphocyte count. AIDS Res. Hum. Retroviruses 6: 553-561.
5. Banks, N. D., N. Kinsey, J. Clements and J. E. K. Hildreth. 2002. Sustained antibody-dependent cell-mediated cytoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18: 1197-1205.
6. mac251. J. Immunol. 174: 2185-2189.
7. Forthal, D., G. Landucci, M. Marthas, and K. Van Rompay. 2005. Non-neutralizing antibody that prevents SIV infection in neonatal rhesus macaques (RHMS) potently inhibits SIV in an antibody-dependent cell-mediated virus inhibition (ADCVI) assay. In AIDS Vaccine Meeting, September 6-9. Montreal. Quebec, Canada, p. 50.
8. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75: 6953-6961.
9. mac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 78: 2212-2221.
10. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73: 4009-4018.
11. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347.
12. Ferrantelli, F., R. A. Rasmussen, K. A. Buckley, P-L. Li, T. Wang, D.C. Montefiori, H. Katinger, G. Stiegler, D. C. Anderson, H. M. McClure, and R. M. Ruprecht. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189: 2167-2173.
13. Nishimura, Y., T. Igarashi, N. L. Haigwood, R. Sadjadpour, O. K. Donau, C. Buckler, R. J. Plishka, A. Buckler-White, and M. A. Martin. 2003. Transfer of neutralizing IgG to macaques 6 h by not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 100: 15131-15136.
14. Haigwood, N. L., D. Montefiori, W. F. Sutton, J. McClure, A. J. Watson, G. Voss, V. M. Hirsch, B. A. Richardson, N. L. Letvin, S. L. Hu and P. R. Johnson. 2004. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78: 5983-5995.
15. Van Rompay, K. K. A., C. J. Berardi, S. Dillard-Telm, R. P. Tarara, D. R. Canfield, C. R. Valverde, D. C. Montefiori, K. Stefane Cole, R. C. Montelaro, C. J. Miller, and M. L. Marthas. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177: 1247-1259.
16. Van Rompay, K. K. 2005. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments. AIDS Rev. 7: 67-83.
17. Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas. 1999. Early short-term 9-[2-R-(Phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73: 2947-2955.
18. Van Rompay, K. K. A., K. Abel, J. R. Lawson, R. P. Singh, K. A. Schmidt, T. Evans, P. Earl, D. Harvey, G. Franchini, J. Tartaglia, et al. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38: 124-134.
19. Zhao, J., J. Pinczewski, V. R. Gomez-Roman, D. Venzon, V. S. Kalyanaraman, P. D. Markham, K. Aldrich, M. Moake, D. C. Montefiori, Y. Lou, et al. 2003. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIVmac251 challenge by a replication competent Ad5hr-SIVenv/rev and Ad5hr-SIV gag recombinant priming/gp120 boosting regimen. J. Virol. 77: 8354-8365.
20. National Research Council. 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
21. Van Rompay, K. K., J. L. Greenier, K. S. Cole, P. Earl, B. Moss, J. D. Steckbeck, B. Pahar, T. Rourke, R. C. Montelaro, D. R. Canfield, et al. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77: 179-190.
22. + cell mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 78: 5324-5337.
23. Gomez-Roman, V. R., R. H. Florese, L. J. Patterson, B. Peng, D. Venzon, K. Aldrich, and M. Robert-Guroff. 2006. A simplified method for the rapid fluorometric assessment of antibody-dependent cell mediated cytotoxicity. J. Immunol. Methods 308: 53-67.
24. Forthal, D. N., and G. Landucci. 1998. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J. Immunol. Methods 220: 129-138.
25. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Chen, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus-SIV env vaccine elicits humoral, cellular and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol 71: 8531-8541.
26. Otsyula, M., C. Miller, M. L. Marthas, K. K. Van Rompay, J. Collins, N. Pedersen, and M. McChesney. 1996. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr. Res. 39: 630-635.
27. Chackerian, B., N. L. Haigwood, and J. Overbaugh. 1995. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213: 386-394.
28. Mahalanabis, M., V. M. Hirsch, and N. L. Haigwood. 2005. Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity. J. Med. Primatol. 34: 253-261.
29. Weinhold, K J. 1990. Nonrestricted forms of anti-HIV-1 cytotoxicity. In Techniques in HIV Research. A. Aldovini and B. D. Walker, eds. Stockton Press, New York, pp. 187-199.
30. DeMaria, M. A., M. Casto, M. O'Connell, R. P. Johnson, and M. Rosenzweig. 2000. Characterization of lymphocyte subsets in rhesus macaques during the first year of life. Eur. J. Haematol. 65: 245-257.
31. Van Rompay, K. K. A., R. P. Singh, L. L. Brignolo, J. R. Lawson, K. A. Schnidt, B. Pahar, D. R. Canfield, R. P. Tarara, D. L. Sodora, N. Bischofberger, and M. L. Marthas. 2004. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J. Acquir. Immune Defic. Syndr. 36: 900-914.
32. Pal, R., D. Venzon, N. L. Letvin, S. Santra, D. C. Montefiori, N. R. Miller, E. Tryniszewska, M. G. Lewis, T. C. VanCott, V. Hirsch, et al. 2002. ALVAC-SIV gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76: 292-302.
33. Benlhassan-Chahour, K., C. Penit, V. Dioszehgy, F. Vasseur, G. Janvier, Y. Riviere, N. Dereuddre-Bosquet, D. Dormont, R. Le Grand, and B. Vaslin. 2003. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J. Virol. 77: 12479-12493.
34. Haase, A. T. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5: 783-792.
35. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
36. Hezareh, M., A. J. Hessell, R. C. Jensen, J. G. J. Van de Winkel, and P. W. H. I. Parren. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75: 12161-12168.
37. Amedee, A. M., J. Rychert, N. Lacour, L. Fresh, and M. Ratterree. 2004. Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 1: 17.
38. Milush, J. M., D. Kosub, M. Marthas, K. Schmidt, F. Scott, A. Wozniakowski, C. Brown, S. Westmoreland, and D. L. Sodora. 2004. Rapid dissemination of SIV following oral inoculation. AIDS 18: 2371-2380.
39. Miller, C. J., Q. Li, K. Abel, E.-Y. Kim, Z.-M. Ma, S. Wietgrefe, L. La Franco-Scheuch, L. Compton, L. Duan, M. Dykhuizen Shore, et al. 2005. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79: 9217-9227.
40. Rappocciolo, G., J. S. Allan, J. W. Eichberg, and T. C. Chanh. 1992. A comparative study of natural killer cell activity, lymphoproliferation, and cell phenotypes in nonhuman primates. Vet. Pathol. 29: 53-59.
41. Merrill, J. D., M. Sigaroudinia, and S. Kohl. 1996. Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells. Pediatr. Res. 40: 498-503.
42. Patterson, L. J., N. Malkevitch, J. Pinczewski, D. Venzon, Y. Lou, B. Peng, C. Munch, M. Leonard, E. Richardson, K. Aldrich, et al. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77: 8607-8620.
43. Malkevitch, N., L. J. Patterson, K. Aldrich, E. Richardson, W. G. Alvord, and M. Robert-Guroff. 2003. A replication competent Ad5hr-SIV recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in mamu-A*01 rhesus macaques. J. Immunol. 170: 4281-4289.